Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • XRX-225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Annual & Special Meeting of Shareholders
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Analyst Coverage
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Annual & Special Meeting of Shareholders
  • Email Alerts
Sep 15, 2020 7:00am EDT

XORTX Highlights New Studies of Acute Kidney Disease Due to COVID-19 Infection

Aug 31, 2020 7:00am EDT

XORTX Files U.S. FDA Pre-IND Meeting Request for XRx-101 (Oxypurinol) COVID-19 Program and Pre-IND Meeting Submission

Aug 28, 2020 6:37pm EDT

XORTX Announces Change to Board of Directors

Aug 07, 2020 7:00am EDT

XORTX Appoints Dr. David Sans in New York as Director Corporate Development

Aug 04, 2020 10:11am EDT

XORTX Partners with Mount Sinai’s Icahn School of Medicine on US-based Clinical Trial in COVID-19

Jun 23, 2020 7:00am EDT

XORTX Announces Mr. Anthony J. Giovinazzo to Join as Special Advisor to the Board of Directors

May 19, 2020 9:38am EDT

XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus / COVID-19 Programs

Apr 30, 2020 9:02am EDT

XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials

Apr 30, 2020 8:30am EDT

XORTX Provides Overview and Update of Key Activities

Mar 26, 2020 7:00am EDT

XORTX Announces New Clinical Advisory Board Member

  • arrow_back
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap